SBCM
PDLI

Silver Bridge Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Silver Bridge Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-26,868
Closed -$207K – 233
2013
Q2 		$207K Buy
+26,868
New +$210K 0.04% 229

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Silver Bridge Capital Management's PDLI Position: Q3 2013 in Review

Silver Bridge Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2013, closing a stake of 26,868 shares — an estimated $207K sold.

Silver Bridge Capital Management first reported a position in PDLI in Q2 2013 and held it in 1 quarter. The position peaked at $207K in Q2 2013. 212 funds tracked by Wall St. Rank hold PDLI as of Q3 2013.

  • Silver Bridge Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2013 after selling out during the quarter.
  • Silver Bridge Capital Management sold 26,868 PDL BioPharma, Inc. shares in Q3 2013, an estimated $207K.
  • Silver Bridge Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 1 quarter.
  • Silver Bridge Capital Management's PDL BioPharma, Inc. position peaked at $207K in Q2 2013.
  • 212 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2013.

Based on Silver Bridge Capital Management's 13F filing for Q3 2013.